www.investegate.co.uk · · GB
Divestment of Acrylate Monomers
Executive Summary
AI-generatedSynthomer plc announced an agreement to divest its Acrylate Monomers business, operating through Synthomer a.s. in the Czech Republic, to Mutares SE & Co KGaA. This move is part of Synthomer's strategic plan to simplify its portfolio by removing a cyclical and capital-intensive base chemicals operation. The transaction aims to improve profitability and cash generation, allowing the company to focus on higher-margin specialty chemical markets.
Synthomer plc is simplifying its portfolio by divesting a non-core, capital-intensive segment (Acrylate Monomers). This move primarily affects Synthomer's internal cost structure and profitability (gross margin) but does not signal an immediate market supply shock or commodity price change for acrylate monomers. The impact is single-company/supply-chain-specific.
Key Insights
- Synthomer is divesting Acrylate Monomers, an operating company in the Czech Republic, to Mutares SE & Co KGaA.
- The divested business was deemed non-core and highly capital-intensive, requiring approximately €5m in annual capital expenditure.
- This divestment will allow Synthomer to sharpen its focus on higher-margin specialty chemicals markets.
- Acrylate Monomers generated external sales of €68m in the year ended 31 December 2025 but recorded a standalone adjusted EBITDA loss of €10m.
- The transaction is expected to close by the end of Q3 2026, with consideration structured as cash generation sharing up to €12m over three years.
Topic context
The full article is on the original publisher site.